MOGLU is a noninvasive continuous glucose monitoring (CGM) device designed to revolutionize diabetes care. Using innovative Raman spectroscopy technology, it detects glucose-reactive signals on the skin, reducing costs and enhancing convenience. We are the only team worldwide to directly observe in vivo Raman signals for glucose. Since 2023, we've collaborated with Professor Peter So's team at MIT's Biological Engineering department on clinical trials. We plan to conduct larger trials at the Joslin Diabetes Center later this year and aim for FDA approval in 2025. Our data so far indicates that MOGLU could potentially become the first FDA-approved noninvasive CGM.